Likewise, by grouping breast cancer based on tumor-infiltrating immune cells, a group noticed that compared to the regulatory T-cells and M0 and M2 macrophages group, samples with higher CD8+ T-cells and memory-activated CD4+ T-cells harbor higher expressions of a wide range of immunomodulators (including LAG-3 and PD-L1), and have a significantly higher overall survival [43]. The gene discussed is CD4; the disease is neoplasm.